The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | The importance of considering a CLL patient’s tumor lysis risk status
Matthew Davids, MD, from Dana-Farber Cancer Institute, Boston, MA outlines the importance of being aware of a patient’s tumor lysis risk status in chronic lymphocytic leukemia (CLL). This status can be determined by the the size of their lymph nodes and the height of their lymphocytosis. Dr Davids continues on to emphasize the importance starting venetoclax treatment at a low dose and ramping the dosage up week by week. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
